Design of bioactive compounds.
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D000963:Antimetabolites / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D001665:Binding Sites; D001692:Biological Transport; D002784:Cholesterol / Q000096:biosynthesis; D002875:Chromosomes / Q000187:drug effects; D003520:Cyclophosphamide / Q000494:pharmacology; D004304:Dosage Forms; D005449:Fluorenes / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000378:metabolism / Q000648:ultrastructure; D008938:Mitosis / Q000187:drug effects; D011485:Protein Binding; D011506:Proteins / Q000378:metabolism; D011955:Receptors, Drug; D012995:Solubility; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000378:metabolism
D000924:Anticholesteremic Agents; D000963:Antimetabolites; D004304:Dosage Forms; D005449:Fluorenes; D011506:Proteins; D011955:Receptors, Drug; D013449:Sulfonamides; D003520:Cyclophosphamide; D002784:Cholesterol